Literature DB >> 28224329

Posterior reversible encephalopathy syndrome after long-term treatment with low-dose sunitinib: a case report.

Lorenzo Saraceno1, Vito A G Ricigliano1, Michele Cavalli1, Giovanni Meola2.   

Abstract

Entities:  

Keywords:  Anti-VEGF therapy; Hypertension; Posterior reversible encephalopathy syndrome; Sunitinib

Mesh：

Substances：

Year:  2017        PMID： 28224329     DOI： 10.1007/s10072-017-2851-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

1.  A new case of brainstem variant of posterior reversible encephalopathy syndrome: clinical and radiological features.

Authors:  F Tari Capone; S Candela; A Bozzao; F Orzi
Journal:  Neurol Sci       Date:  2014-11-20       Impact factor: 3.307

2.  Recurrent childhood PRES.

Authors:  Fuldem Yildirim Donmez; Ahmet Muhtesem Agildere
Journal:  Neurol Sci       Date:  2015-04-18       Impact factor: 3.307

Review 3.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors:  Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal:  Target Oncol       Date:  2011-11-17       Impact factor: 4.493

Review 4.  Management of hypertension in angiogenesis inhibitor-treated patients.

Authors:  H Izzedine; S Ederhy; F Goldwasser; J C Soria; G Milano; A Cohen; D Khayat; J P Spano
Journal:  Ann Oncol       Date:  2009-01-15       Impact factor: 32.976

5.  Reversible Posterior Leukoencephalopathy Syndrome Developing After Restart of Sunitinib Therapy for Metastatic Renal Cell Carcinoma.

Authors:  Shinji Fukui; Yuta Toyoshima; Takeshi Inoue; Yoriaki Kagebayashi; Shoji Samma
Journal:  Case Rep Med       Date:  2016-10-04
  5 in total
  1 in total

1.  Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review.

Authors:  Xutong Li; Jie Chai; Zhi Wang; Lin Lu; Qingye Zhao; Jie Zhou; Fang Ju
Journal:  Onco Targets Ther       Date:  2018-07-30       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.